For decades IgA nephropathy had no branded therapy; a nephrologist managed it with blood-pressure control and waited. In four years it has acquired five FDA-approved drugs across four mechanisms, and the competitive-intelligence question has inverted. It is no longer which agent is most effective. It is where each one fits in a treatment sequence that no guideline has yet written.
Five drugs, four mechanisms
The approved field spans four distinct mechanisms. Targeted-release budesonide (Tarpeyo, Calliditas and Otsuka), a gut-directed corticosteroid, came first with accelerated approval in December 2021 and full approval in December 2023. Two endothelin antagonists followed: sparsentan (Filspari, Travere), a dual endothelin and angiotensin blocker carrying a hepatotoxicity REMS, and atrasentan (Vanrafia, Novartis), a selective endothelin-A antagonist approved in April 2025. Iptacopan (Fabhalta, Novartis) inhibits complement factor B, and sibeprenlimab (Voyxact, Otsuka) is a first-in-class anti-APRIL antibody cleared in November 2025. Four are oral, one is subcutaneous, and none was studied against another.
The surrogate endpoint splits the field
Every one of these agents won accelerated approval on the same surrogate, a reduction in proteinuria, and that is where the competitive fault line runs. Payers and HTA bodies increasingly discount the proteinuria surrogate and reward confirmatory evidence on eGFR slope, the measure of kidney-function decline, which so far only budesonide and sparsentan carry. A read that ranks these drugs on headline proteinuria numbers, drawn from separate trials with separate comparators, mistakes cross-trial data for a comparison and misses the endpoint that will actually gate access.
Not every diagnosed patient is treat-worthy
The addressable market is smaller than the diagnosis, because not every patient progresses. Roughly 30 to 40 percent reach kidney failure over 20 to 30 years, so the commercially relevant cohort is the high-risk subset: patients with persistent proteinuria above 1 g/g and a declining eGFR on optimised background therapy. That logic narrows an estimated 70,000 to 90,000 biopsy-diagnosed US patients to a 15,000 to 25,000 treatment-eligible pool. The contest is fought inside that cohort, not across the whole diagnosed population.
CI is a sequencing map, not a feature grid
What a commercial team needs before this launch wave is not a feature comparison but a sequencing map: which mechanism opens therapy, which layers on, which is held for the patient who progresses despite the first, and how the prior-authorisation gate and the sparsentan REMS shape the order. That is a positioning problem in a four-mechanism market, and it is the same discipline the rest of rare disease demands. You segment and sequence before you rank.
A preview of the crowded rare-disease launch
IgA nephropathy is a preview of the modern rare-disease launch, where five mechanisms arrive faster than the evidence to sequence them. The competitive intelligence that helps is the one that maps the sequence and the access gate, not the one that declares a winner. This connects to the wider rare-disease sizing discipline: in a segment-gated, risk-stratified indication, the market is built, not ranked.
AXLRx builds the IgAN competitive map as a sequencing and access read, not a feature grid. See the IgA nephropathy briefs, or commission a model scoped to your asset.